3D Medicines

3D Medicines (3DMed), established in 2010, is a leading organization in precision healthcare in China committed to providing accessible early and personalized diagnosis to every patient. 3DMed has set the benchmark for advancement in automated molecular diagnostics and artificial intelligence (AI) to assist doctors in utilizing genetic data for customized patient treatment. The 3DMed clinical laboratory is endorsed by the College of American Pathologists (CAP) and certified by Clinical Laboratory Improvement Amendments (CLIA) to conduct clinical testing in various disease areas. In 2018, 3DMed introduced an AI-driven cancer genome initiative.